{
    "abstract": "In clinical trials, frontline pembrolizumab for advanced NSCLC has demonstrated durable, clinically meaningful, long-term survival benefits over chemotherapy. Our objective was to evaluate 5-year survival rates outside the idealized setting of clinical trials for advanced/metastatic NSCLC treated with frontline pembrolizumab monotherapy.\nUsing a nationwide, electronic health record-derived, deidentified database in the United States, we studied adult patients with advanced/metastatic NSCLC (unresectable stage IIIB/IIIC, or stage IV), with PD-L1 expression \u2265 50%, no documented EGFR, ALK, or ROS1 genomic alteration, and ECOG performance status of 0-1 initiating frontline pembrolizumab monotherapy from November 1, 2016, through March 31, 2020, excluding those in clinical trials. Kaplan-Meier was used to determine overall survival (OS). Data cutoff was May 31, 2023.\nA total of 804 patients were eligible for the study, including 404 women (50%); median age was 72 years (range, 38-85 years), with 310 patients (39%) \u2265 75 years old. Median follow-up time from pembrolizumab initiation to data cutoff was 60.5 months (range, 38.0-78.7). At data cutoff, 549 patients (68%) had died. Median OS was 19.2 months (95% CI, 16.6-21.4), and survival rate at 5 years was 25.1% (95% CI, 21.7-28.7). Overall, 266 patients (33%) received 1 or more subsequent regimens, most commonly an anti-PD-(L)1 agent (as monotherapy or combination therapy) or platinum-based chemotherapy.\nWith 5-year follow-up in a real-world population, frontline pembrolizumab monotherapy continues to demonstrate long-term effectiveness, with survival outcomes consistent with those of pivotal clinical trials, for treating patients with advanced NSCLC with PD-L1 expression of \u2265 50% and no EGFR, ALK, or ROS1 genomic alteration.",
    "authors": [
        {
            "affiliation": "Perlmutter Cancer Center, New York University Langone Health, New York, NY.",
            "firstname": "Vamsidhar",
            "initials": "V",
            "lastname": "Velcheti"
        },
        {
            "affiliation": "Merck & Co., Inc., Rahway, NJ. Electronic address: pragya.rai@merck.com.",
            "firstname": "Pragya",
            "initials": "P",
            "lastname": "Rai"
        },
        {
            "affiliation": "Merck & Co., Inc., Rahway, NJ.",
            "firstname": "Yu-Han",
            "initials": "YH",
            "lastname": "Kao"
        },
        {
            "affiliation": "Merck & Co., Inc., Rahway, NJ.",
            "firstname": "Diana",
            "initials": "D",
            "lastname": "Chirovsky"
        },
        {
            "affiliation": "Merck & Co., Inc., Rahway, NJ.",
            "firstname": "Ana Tablante",
            "initials": "AT",
            "lastname": "Nunes"
        },
        {
            "affiliation": "Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.",
            "firstname": "Stephen V",
            "initials": "SV",
            "lastname": "Liu"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2024 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, The Author(s). Published by Elsevier Inc. All rights reserved.",
    "doi": "10.1016/j.cllc.2024.05.002",
    "journal": "Clinical lung cancer",
    "keywords": [
        "Advanced nonsmall cell lung cancer",
        "Immunotherapy",
        "Overall survival",
        "Real-world time on treatment",
        "Subsequent therapy"
    ],
    "methods": null,
    "publication_date": "2024-06-17",
    "pubmed_id": "38880664",
    "results": "A total of 804 patients were eligible for the study, including 404 women (50%); median age was 72 years (range, 38-85 years), with 310 patients (39%) \u2265 75 years old. Median follow-up time from pembrolizumab initiation to data cutoff was 60.5 months (range, 38.0-78.7). At data cutoff, 549 patients (68%) had died. Median OS was 19.2 months (95% CI, 16.6-21.4), and survival rate at 5 years was 25.1% (95% CI, 21.7-28.7). Overall, 266 patients (33%) received 1 or more subsequent regimens, most commonly an anti-PD-(L)1 agent (as monotherapy or combination therapy) or platinum-based chemotherapy.",
    "title": "5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression \u2265 50% Advanced NSCLC.",
    "xml": "<Element 'PubmedArticle' at 0x788504a4e930>"
}